SeraCare Offers New HIV Seroconversion Panels for Current Assay Qualification

Share Article

Six new highly characterized seroconversion panels

SeraCare Life Sciences, an industry leader in quality control products, announces six new HIV Seroconversion Panels with enhanced product information including Fiebig stage and 4th generation screening test results. Each panel consists of a set of undiluted plasma samples from a single plasma donor during a period of HIV seroconversion, and is ready to use in vials of 1.0mL per patient sample. Data sheets for each panel list results from twenty U.S. and International test methods for markers of HIV infection, including HIV RNA, 1st to 4th generation screening tests for HIV, confirmatory tests and a rapid discriminatory method. A seroconversion graph of critical data points is also included. Each panel consists of undiluted plasma samples from serial collections from a single deferred plasma donor during very early HIV infection.

Panels with test data from multiple methods are vital for assay development and regulatory compliance. Extensively defined natural patient samples accelerate verification of new test methods, provide a common reference for assay comparison, and are valuable for troubleshooting existing assays. “For more than 20 years, SeraCare’s HIV Seroconversion Panels have contributed to the advancement of research in early HIV infection and improvements in the sensitivity of test methods,” said Michelle Stafford, Senior Product Manager, SeraCare Life Sciences. “We are pleased to be introducing six new Panels with updated data, responding to the needs of researchers and test method developers who use these panels.”

The data for SeraCare’s new HIV-1 Seroconversion Panels will be available at The enhanced on-line data feature allows SeraCare to provide timely updates whenever new test data are available. New seroconversion panels for Hepatitis B and C will be introduced in the coming months.

About SeraCare Life Sciences, Inc.:
SeraCare serves the global life sciences industry by providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics. The Company’s innovative portfolio includes diagnostic controls, plasma-derived reagents and molecular biomarkers, biobanking and contract research services. SeraCare’s quality systems, scientific expertise and state-of-the-art facilities support its customers in meeting the stringent requirements of the highly regulated life sciences industry.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Christopher Hoag

Email >

Michelle Stafford
Visit website